controlled trials to provide clearer answers to the important questions addressed in the guideline. Data concerning traditional synthetic DMARDs should be updated with randomized controlled trials, and data regarding perioperative management of biologics also needs more definitive study. Patients with rheumatic diseases have higher rates of concomitant metabolic syndrome and cardiac disease and may also be at potentially higher risk of perioperative cardiac and/or thromboembolic events.